Forbes April 18, 2024
TOPLINE
Weight loss and diabetes may just be the beginning for drugs like Ozempic, Wegovy, Mounjaro and Zepbound as reports increasingly suggest they may have far-reaching benefits for treating conditions as diverse as heart and liver disease, Parkinson’s, anxiety and addiction, sparking research among firms competing in pharma’s latest gold rush.
KEY FACTS
Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound — brand names for drugs semaglutide and tirzepatide — are far and away the most famous members of a booming class of medications known as GLP-1 agonists, which mimic the function of a gut hormone involved in regulating blood sugar and appetite, glucagon-like peptide-1.
GLP-1 drugs were initially approved to treat diabetes and, more...
Today's Sponsors
Today's Sponsor